HANGZHOU, China, August 12, 2021 / PRNewswire / – Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as “Lynk Pharmaceuticals”), an innovative drug development company, today announced that it has administered its triple kinase inhibitor LNK01002 to the first patient in a Phase I clinical trial. This is an open-label, multicenter, phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of LNK01002 in patients with primary myelofibrosis (PMF) and secondary myelofibrosis (PV / ET-MF) induced by an essential polycythemia or a primary thrombocytosis.
LNK01002 is an innovative triple kinase inhibitor independently developed by Lynk Pharmaceuticals. LNK01002 simultaneously targets three kinase motors of PMF and PV / ET-MF with the potential to effectively treat patients who are unresponsive or who have developed resistance to conventional therapies and thereby addresses a global clinical need unmet with potential therapy first class.
“In preclinical studies, we have demonstrated better anticancer activity and better safety compared to other mono- or bi-kinase inhibitors,” said Dr. Sherry Weigand, Medical Director of Lynk Pharmaceuticals, “Rapid clinical studies of LNK01002 in patients will accelerate the assessment of its therapeutic value more quickly and in greater depth. As a new therapy, we hope that LNK01002 will benefit patients in need as soon as possible. “
“This first patient study of LNK01002 is an important milestone, as it officially marks the start of its clinical phase of studies.” said Zhao-Kui (ZK) Wan, Founder and CEO of Lynk, “We look forward to seeing the clinical results and hope that LNK01002 will bring better and more treatment to patients around the world.”
About Lynk Pharmaceuticals:
Lynk Pharmaceuticals, a clinical stage company, was founded in 2018 by senior drug R&D experts and executives from Pfizer, Merck and Johnson & Johnson. Lynk Pharmaceuticals is dedicated to the discovery and development of innovative drugs for the treatment of cancer, as well as immune and inflammatory diseases. Driven by a higher goal, Lynk Pharmaceuticals aims to be a market leader in meeting unmet medical demands through the development of innovative therapies. To date, Lynk Pharmaceuticals has independently developed a number of new innovative Class I clinical drugs and, independently and jointly with its US partner, has initiated a number of clinical studies globally. For more information on Lynk Pharmaceuticals, please visit: https://www.lynkpharma.com.
SOURCE Lynk Pharmaceuticals Co., Ltd.